Multi-Disciplinary Program Hones Biomedical Commercialization Skills for Early-Career Scientists, Clinicians and Business Students
December 17, 2024
Accelerating BioVenture Innovation (ABI) program Dec. 5 graduated another cohort with its signature pitch finale in Uris Auditorium and a networking reception. The ABI course is one of the anchor programs developed by BioVenture eLab to create a culture and environment of entrepreneurial thinking, as well as resources and industry professionals to spin out companies from Weill Cornell Medicine.
Licensing of PDX Model Repository Can Benefit Cancer Research Community
December 2, 2024
In October, Weill Cornell Medicine and Champions Oncology signed a licensing agreement allowing Champions Oncology to distribute and commercialize its extensive bank of hematological PDX models, generated by Dr. Giorgio Inghirami, a professor of pathology and laboratory medicine at Weill Cornell Medicine and a member of the Englander Institute for Precision Medicine and Sandra and Edward Meyer Cancer Center. Under the licensing agreement, Champions Oncology has secured the rights to distribute these models to academic institutions and other laboratories on a worldwide basis.
In-House Gene Therapy Core Facility Helps Move Novel Products from the Bench to the Clinic
November 19, 2024
With the 25th anniversary of the Belfer Gene Therapy Core Facility approaching next year, Dr. Stephen Kaminsky, professor of research in genetic medicine and associate director of the facility, shared with us the history and successes of this cutting-edge research facility. It has played a vital role in supporting Cornell University, the National Institutes of Health (NIH) and other U.S. and international investigators in constructing, producing and testing clinical gene therapy vectors.
New Genetic Signatures Can Classify Breast Cancers and Guide Prognosis
October 4, 2024
Researchers at Weill Cornell Medicine have developed breast cancer cell-of-origin signatures that can better predict both overall and progression-free survival of patients with breast cancer compared to previously developed genomic signatures.
The Englander Institute for Precision Medicine Receives Gift from Investment Firm to Support Its Innovative Cancer Therapeutic Research
October 4, 2024
The Medical Excellence Foundation (MEF) pledged to Weill Cornell Medicine a two-year, $200,000 philanthropic gift to support the work of Dr. Olivier Elemento, director of the Englander Institute for Precision Medicine (EIPM) and a professor of physiology and biophysics.
From Scientist to Entrepreneur: Dr. Annie De Groot Shared Her Personal Journey of Helping Discover Immune Boosting Drugs
September 17, 2024
From watching her father perform experiments in the laboratory to working alongside prominent researchers at the National Institutes of Health (NIH), Dr. Annie De Groot’s definition of ‘a physician scientist’ evolved to include entrepreneur. While building her career, she discovered a passion for translational immunology research and founded EpiVax, an immunoinformatics platform company that helps develop findings in the lab into therapeutics for clinical trials.
Dr. Paraskevi Giannakakou Named 2024 XSeed Award Winner
September 11, 2024
Dr. Paraskevi Giannakakou, professor of pharmacology in medicine, was one of the winners of the fourth annual XSeed Award, Cure announced in ceremonies in New York City on Sep. 10. The XSeed Award supports women- and minority-led life science startups in New York City by providing critical funding to bridge the gap from promising preclinical drug development research to the marketplace and commercial success.
Preclinical Model Offers New Insights into Parkinson’s Disease Process
July 23, 2024
A new preclinical model offers a unique platform for studying the Parkinson’s disease process and suggests a relatively easy method for detecting the disease in people, according to a study led by Weill Cornell Medicine researchers.
Prestigious MERIT Grant Funds Research on How the Immune System Can Banish HIV
July 17, 2024
Weill Cornell Medicine has received $4.2 million to study how the immune system in some people infected with HIV can keep the virus under control, which could lead to novel therapeutic strategies for thwarting or eliminating HIV. Dr. Brad Jones, associate professor of immunology in medicine in the Division of Infectious Diseases at Weill Cornell Medicine, was awarded a MERIT grant from the National Institute for Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH).
Machine Learning Helps Define New Subtypes of Parkinson’s Disease
July 16, 2024
Researchers at Weill Cornell Medicine have used machine learning to define three subtypes of Parkinson’s disease based on the pace at which the disease progresses. In addition to having the potential to become an important diagnostic and prognostic tool, these subtypes are marked by distinct driver genes. If validated, these markers could also suggest ways the subtypes can be targeted with new and existing drugs.
The research was published on July 10 in npj Digital Medicine.